Summary Cycling cells are recognised to be more susceptible than quiescent cells to the cytotoxic action of many commonly used cancer chemotherapeutic agents. We have found that oestrogen stimulation of T-47D human breast cancer cells is accompanied by a two-fold increase in VP-16-induced DNA cleavage as measured by alkaline DNA unwinding, and that this increase in DNA cleavage is accompanied by a corresponding enhancement of drug-induced cytostasis. The (Kuo, 1981) or changes in DNA superhelicity (Lipetz et al., (1982) .
Oestrogen stimulation potentiates the cytotoxicity of Sphase-active drugs in synchronised human breast cancer cells in vitro (Weichselbaum et al., 1978) . DNA cleavage induced by non-phase-specific drugs such as m-AMSA has also been reported to be enhanced by oestrogen 'priming' of unsynchronised human breast cancer cell cultures (Zwelling et al., 1983) , but the extent to which this DNA cleavage is reponsible for cytotoxicity remains uncertain. Moreover, it is not known whether such enhancement of DNA cleavage reflects changes in chromatin structure induced by oestrogen, such as changes in accessibility of chromatin to drug interaction (Kuo, 1981) or changes in DNA superhelicity (Lipetz et al., (1982) .
Clinical trials using tamoxifen synchronisation and subsequent oestrogenic 'recruitment' prior to cytotoxic therapy of breast cancer have been undertaken (Eisenhauer et al., 1984; Lippman et al., 1984; Paridaens et al., 1985; Conte et al., 1987) but have so far failed to demonstrate any significant overall survival benefit (Davidson & Lippman, 1987) . Part of the difficulty in applying this strategy successfully in vivo may relate to optimal scheduling of cytotoxic therapy (especially S-phase-specific drugs) and reversal of tamoxifeninduced cytostasis (Furr & Jordan, 1984) . Here we report our findings using oestrogen priming of unsynchronised T-47D human breast cancer cells prior to and show that this results in enhanced DNA cleavage which occurs independently of enhanced DNA synthesis or measurable chromatin modification, and which is also accompanied by enhanced toxicity.
Materials and methods
Cell culture, hormone stimulation and cell growth T-47D cells were obtained from the American Type Culture Collection (Rockville, MD) in their 84th passage. Cell stocks were maintained as monolayer cultures in RPMI plus 10% foetal calf serum, glutamine and antibiotics (subsequently referred to as complete medium) and incubated at 37°C in 5% CO2 in air. For three weeks prior to experiments involving hormone stimulation, cells were cultured in medium supplemented with 5% dextran-charcoal-stripped srum (Reddel et al., 1984) (Ahnstrom & Erixon, 1973) . DNA unwinding was determined by fluorometry using a bisbenzamide dye (Latt & Stetten, 1976) . As described previously (Smith et al., 1986) , treated cell monolayers were frozen and then detached by rapid thawing. Following resuspension in ice-cold buffer, 0.5ml aliquots of the cell suspension were analysed using the method developed by Kanter & Schwartz (1982 (Kohn et al., 1976) .
(b) Nucleoid sedimentation As originally described by Cook & Brazell (1975) NaCl and 1pM Hoechst-33342 at pH 8.0. Cells were then lysed for 30 min at room temperature prior to centrifugation for 30 min at 50,000g. For titration experiments designed to measure the superhelicity of these histone-depleted nucleoid structures (Lipetz et al., 1982) , ethidium bromide was incorporated into both the lysis buffer and the sucrose gradient at the specified concentration in lieu of Hoechst-33342. Transcriptionally active chromatin is known to exhibit increased sensitivity to nuclease-induced DNA nicking (Gazit & Cedar, 1980 wells. Cell monolayers were washed with PBS containing 0.02% EDTA and 0.1% sodium azide and then removed using a rubber policeman. Cells were centrifuged, resuspended at a density of 5 x 107 cellsml-1, and lysed.
Lysates were prepared by boiling cells in SDS and 50mM dithiothreitol, alkylating with 100mM iodoacetamide, shearing the DNA by repeated passage through a 26-gauge needle, and diluting in Nonidet P40. Samples were then incubated in microtitre plates. A second anti-myc mono- clonal antibody conjugated to alkaline phosphatase then recognised captured human myc protein, and bound alkaline phosphatase was detected colorimetrically. The reaction was stopped with acid and optical density determined at 494nm.
Flow cytometry
Following trypsin/EDTA detachment, cells were stained with ethidium bromide 50 ugml-1 plus 0.125% Triton X-100 (Taylor & Milthorpe, 1980) and ribonuclease 0.5mgml-1 for 10min prior to analysis. Samples were monitored using a flow cytometer incorporating an Innova 70-5 argon laser (Coherent, Palo Alto, CA) tuned to 488 nm at 200 mV. DNA fluorescence distributions were analysed by computer using a cell-cycle phase-fitting programme which assumes normal distributions for GI aand G2M phase populations and which calculates a probability function for the S phase distribution based upon the means and standard deviations of the GI and G2M phase (Watson et al., 1987) . In Figure 2 , the oestrogen concentration which optimally stimulates cell growth (represented in Figure 2a as minimal doubling time) corresponds to the optimal concentration for enhancement of VP-16-induced DNA cleavage (Figure 2b ) and VP-16-induced cell growth retardation (Figure 2c ). These data suggest a relationship between the growthstimulatory effect of oestrogen and the observed enhancement of VP-16-induced DNA damage.
(ii) Effect of inhibitors on oestrogen-induced DNA damage enhancement Inhibition of the growth-stimulatory effect of oestrogen using a potent antioestrogen, 4-hydroxytamoxifen, results in antagonism of the observed enhancement of VP-16-induced DNA cleavage (Figure 3a) . Simultaneous exposure of cells to oestrogen and the protein synthesis inhibitor, cycloheximide, also leads to antagonism of this effect (Figure 3b ). However, inhibition of DNA synthesis using the DNA polymerase inhibitor aphidicolin does not affect the enhancement of DNA cleavage seen in oestrogen-primed cells (Figure 3c ). These findings suggest that the enhancing effect of oestrogen on VP-16-induced DNA cleavage is mediated at some point by new protein synthesis but not by entry of cells into DNA synthesis.
(iii) Influence of oestrogen of DNA doublestrandedness and chromatin structure Oestrogen stimulation of up to 72h duration failed to cause any change in DNA scission as measured by nucleoid sedimentation (Figure 4a) , and similar results were observed in cells simultaneously treated with the poly(ADP-ribosyl) transferase inhibitor 3-aminobenzamide (data not shown), suggesting that oestrogen stimulation alone may not be associated with either long-lived or transient DNA strandbreak induction. DNA cleavage was also measured by alkaline unwinding in cells treated with oestrogen for 24h, and no effect was seen over a 3 h unwinding period ( Figure  4a ). This implies that pre-existing DNA cleavage in samples not exposed to drug does not contribute to the observed Figure 4b , which shows that a similar amount of ethidium bromide is required to 'untwist' negatively supercoiled DNA (thereby resulting in minimum sedimentation) in both oestrogen-treated and control cells. Chromatin accessibility to drug treatment appears to be similarly unaffected by oestrogen in either viable (Figure 4c ) or freeze-thaw-permeabilised (Figure 4d ) cells, since the induction of strand-breaks by either bleomycin or DNase II respectively is unchanged in cells stimulated for 24h. also reaches double control levels in cells stimulated for 24 h, and -50% of this increase is achieved within 8 h ( Figure   5b ). In contrast, no change in tritiated thymidine incorporation (Figure 5c ), fraction of cells involved in DNA synthesis (Figure 5d ), or rate of cell-cycle traverse ( Figure  5e ) is measurable after 8 h oestrogen stimulation (Figure 5c ). This sequence of events suggests that oestrogen-induced mitogenesis per se is preceded by very early changes in protein (such as c-myc) synthesis, and that the observed enhancement of VP-16-induced DNA cleavage is related to an intermediate phase of cell activation which precedes stimulation of DNA synthesis.
Discussion
The finding that oestrogen-stimulated T-47D cells sustain higher levels of VP-16-induced DNA cleavage (Figure 2b ) and VP-16-induced cytostasis (Figure 2c) Estey et al., 1987) . This is an important point if such observations are to serve as the basis of new strategies for improving the therapeutic index of clinical cancer therapy. The effects of cycloheximide and aphidicolin on VP-16-induced DNA cleavage in oestrogen-primed cells are in strong agreement with those reported by Chow & Ross (1987) for the effects of these inhibitors on enhanced cleavage seen in synchronised cultures released from quiescence. The inhibitory effect of cycloheximide documented in both reports indicates that the enhanced drug-induced DNA cleavage witnessed in activated cell cultures is dependent at some point on new protein synthesis. This is perhaps not surprising given the very early protein synthetic events detectable immediately following stimulation ( Figure Sa) , events which presumably play an important role in the sequential cascade of mitogenic activation. On the other hand, the lack of antagonism induced by aphidicolin in both studies suggests that enhancement of VP-16-induced DNA cleavage occurs predominantly, if not exclusively, within activated GI-phase cells. This scenario is clearly more attractive for the design of clinical trials based on target cell stimulation than is a strategy dependent upon highly schedule-specific administration of S-phase-active drugs.
That the enhancement of VP-16-induced DNA cleavage does indeed occur in Gl-phase cells is further supported by the data presented in Figure 5 , which shows that VP-16-induced DNA cleavage is enhanced several hours prior to enhancement of DNA synthesis. Since c-myc protein levels are increased only two-fold by oestrogen stimulation of this cell system -whereas numerous studies of synchronised cell systems confirm a ten-fold increment in the expression of this gene following release of cells from quiescence (Kelly et al., 1983; Dean et al., 1986 ) -the possibility exists that only a fraction of the T-47D cell population is activated by oestrogen exposure. This hypothesis is consistent with the relatively small increase in S-phase cells documented after 24h oestrogen exposure (Figure 5d ). Furthermore, if only a subpopulation of GI-phase cells is in fact activated by oestrogen, the observed overall two-fold enhancement of VP-16-induced DNA cleavage could represent a gross underestimate of true DNA cleavage enhancement in the putative oestrogen-activated cell subset. Flow cytometric studies are now underway to clarify this issue by examining the effect of VP-16-induced DNA damage at the single-cell level.
There is now much evidence suggesting that most VP-16-induced DNA cleavage revealed by alkali-or proteinasebased DNA damage assays represents stabilised 'cleavable complexes' of DNA and the intranuclear enzyme topoisomerase II (Chen et al., 1984; Ross et al., 1984) . The importance of chromatin structure (addressed in Figure 4 ) in mediating this type of DNA lesion has been highlighted by the work of Udvardy & Schedl (1986) . Absolute levels of topoisomerase II have, moreover, recently been recognised to be higher in proliferating than in quiescent cells (Heck & Earnshaw, 1986) . However, the report that enzyme levels (as determined by immunoblotting) rise only in S-and G2-phase cells following stimulation -even though enhancement of VP-16-induced DNA cleavage is unaffected by inhibition of DNA synthesis using aphidicolin (Chow & Ross, 1987) suggests that enzyme activation within GI-phase cells may accompany cellular activation, a model supported by the data presented here. Indeed, in vitro data have already implicated phosphorylation (Ackerman et al., 1985) , poly(ADP-ribosyl)ation (Darby et al., 1985) and calciummediated pathways (Osheroff & Zechiedrich, 1987) 
